Molecular target
Estrogen Receptor (ERα / ERβ)
Nuclear receptors mediating estrogen's reproductive, cardiovascular, bone, and CNS effects. Targeted by HRT (estradiol), oral contraceptives (ethinyl estradiol), and SERMs (tamoxifen, raloxifene). Phytoestrogens (genistein, daidzein, formononetin, biochanin A, glycitein, coumestrol, lignans) bind ER with preferential ERβ affinity, giving rise to a complex partial-agonist profile.
Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.
No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.
Pharmaceutical agents
Drugs that act on Estrogen Receptor (ERα / ERβ)
These medications have Estrogen Receptor (ERα / ERβ) among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.
Botanical connections
Plants whose compounds act on Estrogen Receptor (ERα / ERβ)
Each plant below contains a named compound documented to act on Estrogen Receptor (ERα / ERβ). The compound and the reason for the connection are shown on every edge — a shared mechanism, not a therapeutic equivalence.
- FormononetinIsoflavone
Methylated isoflavone; gut-converted to daidzein, then potentially to equol. The signature red clover phytoestrogen.
- Biochanin AIsoflavone
Methylated genistein precursor; more abundant in red clover than in soy.
- Genistein, daidzeinIsoflavone
Same isoflavones as soy but at lower concentrations.
- Shatavarins I-IVSteroidal saponin
Primary phytoestrogen-active steroidal saponins. Basis for the women's-reproductive-health traditional use and the hormonal-class interaction warning.
- Polyphenols / isoflavonesPolyphenol
Antioxidant flavonoids contributing to overall adaptogenic profile.
- Phytoecdysteroids / ecdysteroneSterone
Wang et al. (2020) proposed an estrogen-like pathway mediating renoprotective effects in LPS-induced acute kidney injury models; binding specificity to ERα/ERβ described as indirect/secondary.
- Casticin + iridoidsflavonoid + iridoid
Mild estrogen-receptor activity contributes to the broader hormonal-axis modulation observed clinically; mechanism not as central as the dopaminergic action.
- Secoisolariciresinol diglucoside (SDG)lignan precursor
Gut microbial conversion to enterodiol and enterolactone (mammalian lignans) — weak estrogen-receptor agonist/antagonist activity, providing the modest hormonal modulation observed in menopausal trials and the breast-cancer-prevention signal in observational studies.
- AnetholePhenylpropanoid
Anethole has been reported to interact with estrogen receptors in preclinical models, consistent with observed mild estrogenic activity of the whole seed; reviewed in Shojaii et al. 2012 (PMID 22848853).
- SclareolLabdane diterpene
Estrogenic activity has been attributed to sclareol in ethnobotanical and pharmacognosy literature; however, none of the cited papers provide in vitro or in vivo data on estrogen-receptor activity for sclareol or any clary sage constituent. The ESTROGEN_R target is included here as a traditional-use and pharmacognosy-literature attribution only; clinical or laboratory evidence of this mechanism is not established by the currently cited evidence pack.
- Anetholephenylpropene
Weak estrogen-receptor agonist; the principal mechanism for traditional galactagogue and dysmenorrhea uses, and for the modest hormone-modulating effects observed in human menopausal trials.
- 8-PrenylnaringeninPrenylflavonoid (potent phytoestrogen)
Among the most potent phytoestrogens characterized — substantially more potent than soy genistein at ER. Basis for the HIGH-impact phytoestrogen interaction warnings with hormonal therapies, tamoxifen.
- GenisteinIsoflavone
Beyond estrogen-receptor binding, genistein is a classically characterized protein-tyrosine-kinase inhibitor and has been studied for anti-angiogenic (VEGF) activity in preclinical cancer models. Research only — not a treatment claim.
- ApigeninFlavone
Apigenin has demonstrated phytoestrogenic activity and inhibition of COX-2/NF-κB pathways in vitro; studied as a possible contributor to reported effects on menopausal symptom indices.
- Isoflavones (formononetin, biochanin A, coumestrol)Phytoestrogen / isoflavonoid
Isoflavones and the coumestan coumestrol are reported in the broader scientific literature to bind estrogen receptors (ERα/ERβ) with weak partial-agonist activity; in vitro studies suggest modulation of aromatase activity. Clinical significance in humans has not been established in rigorous trials. This pharmacological context is not supported by the verified citation pack for this entry.
- Isoflavonoids (formononetin, biochanin A)Isoflavone / Polyphenol
Isoflavonoids in this class are reported to interact with estrogen receptors (ERα/ERβ) as partial agonists/antagonists in related Fabaceae species. Direct receptor-binding data for Baptisia tinctoria-derived isoflavonoids are not established in the available citations; mechanism is extrapolated from the compound class.